Raymond James & Associates Jounce Therapeutics, Inc. Transaction History

Raymond James & Associates

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$6.37 - $10.33 $307,377 - $498,463	-48,254 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$4.58 - $10.95 $156,649 - $374,522	34,203 Added 243.42%	48,254 $394,000
Q2 2020 Jul 28, 2020	BUY	$4.17 - $7.58 $4,666 - $8,482	1,119 Added 8.65%	14,051 $97,000
Q1 2020 Apr 21, 2020	BUY	$2.91 - $8.7 $37,632 - $112,508	12,932 New	12,932 $61,000
Q1 2019 May 06, 2019	SELL	$3.43 - $6.87 $71,896 - $144,002	-20,961 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$2.69 - $6.71 $56,385 - $140,648	20,961 New	20,961 $71,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.